Skip to content

Study · Randomized controlled trial · n = 67 · 1997

3 results

A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.

Kuhn JM, Abourachid H, Brucher P, Doutres JC, Fretin J, Jaupitre A, Jorest R, Lambert D, Petit J, Pin J, Blumberg J, Dufour-Esquerré F

European urology1 Jan 1997Cited by 17 (Europe PMC)

PMID9412795 (opens in a new tab)DOI10.1159/000480796 (opens in a new tab)PepBankPUB-09412795
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with prostate cancer, PSA decreased similarly during triptorelin and leuprolide treatment.

    In plain wordsIn men with prostate cancer, PSA decreased similarly during triptorelin and leuprolide treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePSA reduction
    Study

    n = 67

    Comparator
    Leuprolide 3.75 mg
    Outcome group
    Cancer biomarkers and prognosis · Cancer
    Studied dose
    3.75 mg at 4-week intervals · intramuscular · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    During treatment, PSA dropped similarly in both groups.
    1 context sentence
    Summary · context
    67 patients referred for prostate cancer not suitable for surgery were randomly allocated to two treatment regimens: 33 patients received 3.75 mg Trp i.m. at 4-week intervals for 3 months and 34 patients were treated with 3.75 mg Leu s.c. at the same rhythm of administration for 3 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with prostate cancer, more triptorelin patients than leuprolide patients had testosterone below 1.0 nmol/l by month 2.

    In plain wordsIn men with prostate cancer, more triptorelin patients than leuprolide patients reached the low testosterone threshold by month 2.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTestosterone below threshold at month two
    Study

    n = 67

    Comparator
    Leuprolide 3.75 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg at 4-week intervals · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Testosterone below 1.0 nmol/l
    77%
    triptorelin at month 2
    Testosterone below 1.0 nmol/l
    48%
    leuprolide at month 2

    Source sentences

    Summary
    By month 2, testosterone was < 1.0 nmol/l in 77 and 48% of patients treated with Trp and Leu, respectively (p = 0.02).
    1 context sentence
    Summary · context
    67 patients referred for prostate cancer not suitable for surgery were randomly allocated to two treatment regimens: 33 patients received 3.75 mg Trp i.m. at 4-week intervals for 3 months and 34 patients were treated with 3.75 mg Leu s.c. at the same rhythm of administration for 3 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with prostate cancer, more triptorelin patients than leuprolide patients had testosterone below 1.0 nmol/l after injections.

    In plain wordsIn men with prostate cancer, more triptorelin patients than leuprolide patients reached the low testosterone threshold after injections.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTestosterone below threshold after injection
    Study

    n = 67

    Comparator
    Leuprolide 3.75 mg
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.75 mg at 4-week intervals · intramuscular · 3 monthsAs given in this study (human).

    Measurements

    Testosterone below 1.0 nmol/l
    77%
    triptorelin 24 and 72 h
    Testosterone below 1.0 nmol/l
    56%
    leuprolide 24 and 72 h

    Source sentences

    Summary
    24 and 72 h after GnRHa injection, 77 (Trp) and 56% (Leu) of patients had testosterone < 1.0 nmol/l (p < 0.05).
    1 context sentence
    Summary · context
    67 patients referred for prostate cancer not suitable for surgery were randomly allocated to two treatment regimens: 33 patients received 3.75 mg Trp i.m. at 4-week intervals for 3 months and 34 patients were treated with 3.75 mg Leu s.c. at the same rhythm of administration for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.